USO 24145
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM):Successor-1 (CA057-001)
Disease Types: Multiple Myeloma
Eligibility Requirements:
• Documented diagnosis of MM that is measurable
• Subject must have received 1-3 prior lines of therapy
• One line can contain several phases
• Prior treatment with a lenalidomide required
• Achieved at least MR during 1 prior therapy
• Documented disease progression after last regimen
• ECOG ≤ 2
• Subjects that received prior treatment with mezigdomide or
pomalidomide are excluded
• Subjects that received a prior bortezomib-containing regimen & either
did not achieve at least MR, or had to discontinue bortezomib due to
toxicity are excluded
• Subjects that experienced disease progression either during
treatment with a proteasome inhibitor or within 60 days after the last
dose are excluded
For more information on this trial CLICK HERE .
Available at: